306 related articles for article (PubMed ID: 28389097)
1. Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study.
Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Foster-Nyarko E; Owiafe PK; Ceesay F; Worwui A; Idoko OT; Owolabi O; Bojang A; Jarju S; Drammeh I; Kampmann B; Greenwood BM; Alderson M; Traskine M; Devos N; Schoonbroodt S; Swinnen K; Verlant V; Dobbelaere K; Borys D
Vaccine; 2017 May; 35(19):2531-2542. PubMed ID: 28389097
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.
Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Owiafe PK; Worwui A; Idoko OT; Owolabi O; Kampmann B; Greenwood BM; Alderson M; Traskine M; Swinnen K; Verlant V; Dobbelaere K; Borys D
Vaccine; 2019 May; 37(19):2586-2599. PubMed ID: 30975570
[TBL] [Abstract][Full Text] [Related]
3. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.
Prymula R; Szenborn L; Silfverdal SA; Wysocki J; Albrecht P; Traskine M; Gardev A; Song Y; Borys D
Vaccine; 2017 Aug; 35(35 Pt B):4603-4611. PubMed ID: 28729019
[TBL] [Abstract][Full Text] [Related]
4. Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2-4 years: A phase II randomized study.
Odutola A; Ota MO; Ogundare EO; Antonio M; Owiafe P; Worwui A; Greenwood B; Alderson M; Traskine M; Verlant V; Dobbelaere K; Borys D
Hum Vaccin Immunother; 2016; 12(2):393-402. PubMed ID: 26618243
[TBL] [Abstract][Full Text] [Related]
5. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study.
Leroux-Roels G; Maes C; De Boever F; Traskine M; Rüggeberg JU; Borys D
Vaccine; 2014 Nov; 32(50):6838-46. PubMed ID: 24607003
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial.
Prymula R; Pazdiora P; Traskine M; Rüggeberg JU; Borys D
Vaccine; 2014 May; 32(25):3025-34. PubMed ID: 24699466
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study.
Hammitt LL; Campbell JC; Borys D; Weatherholtz RC; Reid R; Goklish N; Moulton LH; Traskine M; Song Y; Swinnen K; Santosham M; O'Brien KL
Vaccine; 2019 Dec; 37(51):7482-7492. PubMed ID: 31629570
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
[TBL] [Abstract][Full Text] [Related]
9. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage.
Prymula R; Hanovcova I; Splino M; Kriz P; Motlova J; Lebedova V; Lommel P; Kaliskova E; Pascal T; Borys D; Schuerman L
Vaccine; 2011 Feb; 29(10):1959-67. PubMed ID: 21215830
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.
Pauksens K; Nilsson AC; Caubet M; Pascal TG; Van Belle P; Poolman JT; Vandepapelière PG; Verlant V; Vink PE
Clin Vaccine Immunol; 2014 May; 21(5):651-60. PubMed ID: 24599529
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial.
Hammitt LL; Ojal J; Bashraheil M; Morpeth SC; Karani A; Habib A; Borys D; Goldblatt D; Scott JA
PLoS One; 2014; 9(1):e85459. PubMed ID: 24465570
[TBL] [Abstract][Full Text] [Related]
12. Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study.
Zaman K; Zaman SF; Zaman F; Aziz A; Faisal SB; Traskine M; Habib MA; Ruiz-Guiñazú J; Borys D
Vaccine; 2018 Jan; 36(5):698-706. PubMed ID: 29277353
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial.
Sáez-Llorens X; Rowley S; Wong D; Rodríguez M; Calvo A; Troitiño M; Salas A; Vega V; Castrejón MM; Lommel P; Pascal TG; Hausdorff WP; Borys D; Ruiz-Guiñazú J; Ortega-Barría E; Yarzabal JP; Schuerman L
Hum Vaccin Immunother; 2017 Jun; 13(6):1-16. PubMed ID: 28368738
[TBL] [Abstract][Full Text] [Related]
15. Bacterial nasopharyngeal carriage following infant immunization with pneumococcal conjugate vaccines according to a 2+1 schedule in children in South Africa: an exploratory analysis of two clinical trials.
Nunes MC; Moreira M; Koen A; van Niekerk N; Jose L; Cutland CL; François N; Schoonbroodt S; Ruiz-Guiñazú J; Yarzabal JP; Borys D; Schuerman L; Madhi SA
Expert Rev Vaccines; 2020 Dec; 19(12):1177-1189. PubMed ID: 33245004
[No Abstract] [Full Text] [Related]
16. Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland.
Vesikari T; Forsten A; Seppä I; Kaijalainen T; Puumalainen T; Soininen A; Traskine M; Lommel P; Schoonbroodt S; Hezareh M; Moreira M; Borys D; Schuerman L
J Pediatric Infect Dis Soc; 2016 Sep; 5(3):237-248. PubMed ID: 27125273
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
Tregnaghi MW; Sáez-Llorens X; López P; Abate H; Smith E; Pósleman A; Calvo A; Wong D; Cortes-Barbosa C; Ceballos A; Tregnaghi M; Sierra A; Rodriguez M; Troitiño M; Carabajal C; Falaschi A; Leandro A; Castrejón MM; Lepetic A; Lommel P; Hausdorff WP; Borys D; Ruiz Guiñazú J; Ortega-Barría E; Yarzábal JP; Schuerman L;
PLoS Med; 2014 Jun; 11(6):e1001657. PubMed ID: 24892763
[TBL] [Abstract][Full Text] [Related]
18. Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol.
Prymula R; Habib A; François N; Borys D; Schuerman L
Vaccine; 2013 Apr; 31(16):2080-8. PubMed ID: 23391599
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial.
van den Bergh MR; Spijkerman J; François N; Swinnen K; Borys D; Schuerman L; Veenhoven RH; Sanders EA
Pediatr Infect Dis J; 2011 Sep; 30(9):e170-8. PubMed ID: 21487327
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience.
Mrkvan T; Pelton SI; Ruiz-Guiñazú J; Palmu AA; Borys D
Expert Rev Vaccines; 2018 Sep; 17(9):797-818. PubMed ID: 30185083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
